Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape ...

The global vision care products market is projected to reach USD 103.7 billion by 2032, growing at a CAGR of 6.21%. This growth ...

Traditional monofocal lenses primarily correct vision at a single distance. However, innovations in multifocal and trifocal IOLs have allowed patients to achieve improved vision across multiple ...

Get Instant Summarized Text (Gist) Bifocal contact lenses used by young nearsighted children effectively slow myopia progression without losing benefits after discontinuation. In a follow-up study ...

London, UK, 13 January 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing ...

Aspire IOLs address astigmatism, broadening treatable ranges in cataract surgery to <1.0D at the corneal plane. In the US, enVista Aspire is the first Low-Cyl toric IOL below 1.5D at the IOL plane, ...

Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.

efficient unfolding through Bausch + Lomb’s proprietary StableFlex™ Technology, which aids optic recovery. For patients with astigmatism, enVista Aspire Toric IOLs provide a proven option for ...

Bausch + Lomb (BLCO) announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses in the European Union after receiving a CE Mark late last year. enVista Aspire ...

Like enVista MX60E, enVista Aspire offers a glistening-free optic material and controlled, efficient unfolding through Bausch + Lomb’s proprietary StableFlex ™ Technology, which aids optic recovery.